ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1867 • ACR Convergence 2022

    YKL-40-mediated Inflammatory Pathogenesis Common to Polymyositis / Dermatomyositis

    Kazuteru Noguchi1, Tetsuya Furukawa2, Takahiro Yoshikawa1, Mai Morimoto1, Teppei Hashimoto2, Naoto Azuma3 and Kiyoshi Matsui2, 1Hyogo Medical University, Nishinomiya, Japan, 2Hyogo college of Medicine, Nishinomiya, Japan, 3Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

    Background/Purpose: YKL-40 is a chitinase-like protein that is associated with interstitial lung disease in patients with polymyositis (PM)/dermatomyositis (DM) but not with myositis. Myositis pathogenesis…
  • Abstract Number: 1868 • ACR Convergence 2022

    B Cell Count in Juvenile Dermatomyositis: A Biomarker of Disease

    Christopher Costin1, Gabrielle Morgan2, Amer Khojah3 and Lauren Pachman4, 1Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 3Umm Al-Qura University, Makkah, Saudi Arabia, 4Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL

    Background/Purpose: Juvenile Dermatomyositis(JDM) is heterogenous disease with many presentations. The underlying immune pathophysiology of JDM remains complex with varying phenotypes. B Cells remain a critical…
  • Abstract Number: 1858 • ACR Convergence 2022

    A Multi-center Clinical Cohort Study of Chinese Anti-synthetase Syndrome Patients

    mingwei tang1, Qian Wang1, wei Wei2, Pingting Yang3, Xinwang Duan4, Hongbin Li5, Chanyuan Wu6, JIULIANG ZHAO7, jia shi1, Xiaomei Leng8, Xinping Tian1, MENGTAO LI9, Yan Zhao1 and Xiaofeng Zeng10, 1Peking Union Medical College Hospital, Beijing, China, 2Tianjin Medical University General Hospital, Tianjin, China, 3The First Hospital of China Medical University, Shenyang, China, 4the Second Affiliated Hospital of Nanchang University, Nanchang, China, 5Inner Mongolia Medical University, Hohhot City, China, 6Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, 7Beijing Union Medical College Hospital, Beijing, China, 8Peking Union Medical College Hospital, Department of Rheumatology and Clinical Immunology, Beijing, China, 9Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, 10Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: Based on the Chinese Rheumatology Data Center Inflammatory Myopathy Registry (CRDC-MYO), this study aimed to describe the baseline characteristics of a subgroup of patients…
  • Abstract Number: 1866 • ACR Convergence 2022

    Polymyositis/Dermatomyositis Readmissions: Analysis of the Nationwide Readmission Database

    Ehizogie Edigin1, Amy Trang2, Sandhya Shri Kannayiram3, Chinenye Osuorji4, Christopher Hino1, Precious Eseaton5, Solomon Anighoro6, Augustine Manadan2 and Christina Downey7, 1Loma Linda University Health, Loma Linda, CA, 2Rush University Medical Center, Chicago, IL, 3John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, 4Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY, 5University of South Wales, Cardiff, Wales, United Kingdom, 6St. Helens and Knowsley Teaching hospitals NHS Trust, Prescot, England, United Kingdom, 7Loma Linda University Medical Center, Redlands, CA

    Background/Purpose: Polymyositis (PM)/ Dermatomyositis (DM) is a chronic immune-mediated myositis characterized by relapses that can lead to frequent hospitalizations. There is a scarcity of national…
  • Abstract Number: 1879 • ACR Convergence 2022

    Analysis of the Association Between the Atrophic Factors Tripartite Motif Containing (TRIM) 63 and Atrogin-1 and the Clinical and Inflammatory Features of Patients with Idiopathic Inflammatory Myopathies

    jiram torres-Ruiz1, Abdiel Absalón-Aguilar2, Juan Alberto Reyes-Islas2, Alfredo Pérez-Fragoso2, Nancy R Mejía-Domínguez3, guillermo Juárez-Vega4, Alejandro Alfaro-Goldaracena5, Beatriz Alcalá-Carmona2, Guillermo Juárez-Vega3, Fabiola Cassiano-Quezada2 and Diana Gómez-Martín1, 1INCMNSZ, Ciudad de México, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, 3Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Ciudad de México, Mexico, 4Red de Apoyo a la Investigación. UNAM, Ciudad de México, Mexico, 5Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico

    Background/Purpose: Muscle atrophy is mediated by the ubiquitination of myofilaments by two ubiquitin ligases called Tripartite Motif Containing (TRIM) 63 and Atrogin-1, which are induced…
  • Abstract Number: 1873 • ACR Convergence 2022

    Relationship Between Baseline Characteristics of Rheumatoid Arthritis and Types of Mortality: Study of Cohort Followed Prospectively

    Cristina Corrales1, Fabricio Benavides Villanueva1, Ivan Ferraz Amaro2, Nuria Vegas Revenga3, Virgi Portilla4, Ricardo Blanco5, Miguel Ángel González-Gay6 and Alfonso Corrales4, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 3Hospital Galdakao- Usansolo, Galdakao, Spain, 4Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 6Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of mortality mainly due to cardiovascular (CV) events, infections and malignancies. The relationship between the…
  • Abstract Number: 1875 • ACR Convergence 2022

    Assessment of Antibody Levels to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) in Patients with Idiopathic Inflammatory Myopathies Receiving Treatment with Intravenous Immunoglobulin

    Sangmee Bae1, emmanuelle Faure-Kumar1, Jennifer Wang2, Ani Shahbazian2, linh Truong2, Howard Yang2, Maureen McMahon1, John FitzGerald1 and Christina Charles-Schoeman3, 1University of California Los Angeles, Los Angeles, CA, 2UCLA Medical Center, Los Angeles, CA, 3Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA

    Background/Purpose: Antibodies to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) have been reported in pooled donor plasma and intravenous immunoglobulin products (IVIG) since May 2020 (C…
  • Abstract Number: 1871 • ACR Convergence 2022

    Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)

    Zi Ying Li1, Siyi Huang2, Kevin Xi3, Deepan Dalal4 and Anthony Reginato5, 1Roger Williams Medical Center, Providence, RI, 2UCSF Fresno, Fresno, CA, 3Brown University, Providence, 4Brown University School of Medicine, Providence, RI, 5Brown University, Providence, RI

    Background/Purpose: Cardiovascular disease was encountered in 15% of hospital admission from 2016-2017 for patients with idiopathic inflammatory myopathies (IIM) based on the National Inpatient Sample…
  • Abstract Number: 1882 • ACR Convergence 2022

    Efficacy of Immune-apheresis in Patients with Inflammatory Myopathies: A Case Series

    Kastriot Kastrati1, Hanien Rajab2, Anna Rader2, Elisabeth Anna Aichner2, Thomas Karonitsch2, Hans-Peter Kiener2, Michael Bonelli3, Daniel Aletaha4 and Helga Radner3, 1Division of Rheumatology, Vienna, Austria, 2Medical University Vienna, Vienna, Austria, 3Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 4Medical University Vienna, Wien, Austria

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a heterogenous group of acquired autoimmune diseases characterised by inflammation of muscle and affection of other organs, including lung…
  • Abstract Number: 1884 • ACR Convergence 2022

    Idiopathic Inflammatory Myopathies in Alaska Native/American Indian People in Alaska

    Vivek Mehta and Elizabeth Ferucci, Alaska Native Tribal Health Consortium, Anchorage, AK

    Background/Purpose: Racial disparities have been in noted in various autoimmune disorders. Indigenous North American populations have higher prevalence and severity of a number of autoimmune…
  • Abstract Number: 1881 • ACR Convergence 2022

    Association Study Between anti-TIF1γ Antibody and Development of Neoplasia in Three Tertiary Hospitals

    Marina Pavía Pascual1, Isidro Jarque Canalias1, Jose Luis Morell2, Jesús Loarce Martos3, Lorena Montaño Tapia4, Olga Rusinovich1, Natalia de la Torre-Rubio1, Maria Machattou1, Pablo Navarro Palomo1, Maria Carmen Barbadillo Mateos1, Monica Fernandez Castro5, Blanca Garcia-Magallon1, Maria Hildegarda Godoy Tundidor1, Carolina Merino1, JESUS SANZ SANZ1, Jose Luis Andreu1 and Jose Campos1, 1Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 2Hospital Universitario Ramon y Cajal, Madrid, Spain, 3Hospital Universitario Ramón y Cajal, Madrid, Spain, 4Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, 5Puerta de Hierro Hospital, Madrid, Spain

    Background/Purpose: Anti-transcriptional intermediary factor 1γ (anti-TIF 1γ) antibody is robustly linked with malignancy-associated dermatomyositis (DM) in adults, but its specificity varies widely between series. TIF…
  • Abstract Number: 1883 • ACR Convergence 2022

    Auto-antibodies Targeting Membrane Repair Proteins Enhances Myositis Phenotype

    Shane Bruckner1, Kassidy Banford2, hannah Bulgart2, Kevin mcElhanon3, Rohit Aggarwal4, Chester Oddis5, Noah Weisleder1 and Wael Jarjour1, 1The Ohio State University, Columbus, OH, 2The Ohio State University Wexner Medical Center, Columbus, OH, 3Pfizer Inc., Cambridge, MA, 4Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 5University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of disorders in which autoimmune responses produce a chronic state of inflammation resulting in degeneration of skeletal…
  • Abstract Number: 1375 • ACR Convergence 2022

    Short-term Efficacy of Baricitinib in Children with Refractory And/or Severe Juvenile Dermatomyositis

    zhaoling wang1, meiping lu2 and qi zheng1, 1Department of Rheumatology Immunology and Allergy, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, 2Children’s Hospital of Zhejiang University Medical School, Zhejiang, China

    Background/Purpose: To evaluate the short-term efficacy and safety of baricitinib in children withrefractory and/or severe juvenile dermatomyositis (rsJDM) in a real-world setting. Methods: A monocentric…
  • Abstract Number: 1825 • ACR Convergence 2022

    Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study

    Shay Brikman1, Amir Bieber2 and Reuven Mader1, 1Rheumatic Diseases Unit, Emek Medical Center, Afula, Israel, 2Emek Medical Center, Raanana, Israel

    Background/Purpose: Prior studies have shown an association between chondrocalcinosis (CC) and vascular calcifications. In this study, we aimed to assess the presence of vascular calcifications…
  • Abstract Number: 1775 • ACR Convergence 2022

    More Than Half of Patients with Osteoarthritis Have Positive Screening for Fibromyalgia And/or Depression, Feasibly Assessed in Routine Care on Indices Within a Single MDHAQ (multidimensional Health Assessment Questionnaire)

    Theodore Pincus1, Kathryn Gibson2, Juan Schmukler1, Tengfei Li3 and Joel Block1, 1Rush University Medical Center, Chicago, IL, 2Liverpool Hospital, Sydney, Australia, 3Georgetown University, Washington, DC

    Background/Purpose: Osteoarthritis (OA) patients may have widely divergent scores for pain severity vs X-ray joint damage, indicating that elevated OA pain 0-10 visual numeric scale…
  • « Previous Page
  • 1
  • …
  • 605
  • 606
  • 607
  • 608
  • 609
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology